|
Name |
Beauvericin D
|
| Molecular Formula | C44H55N3O9 | |
| IUPAC Name* |
(3S,6R,9S,12R,15S,18R)-3,9,15-tribenzyl-4,10-dimethyl-6,12,18-tri(propan-2-yl)-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone
|
|
| SMILES |
CC(C)[C@@H]1C(=O)N[C@H](C(=O)O[C@@H](C(=O)N([C@H](C(=O)O[C@@H](C(=O)N([C@H](C(=O)O1)CC2=CC=CC=C2)C)C(C)C)CC3=CC=CC=C3)C)C(C)C)CC4=CC=CC=C4
|
|
| InChI |
InChI=1S/C44H55N3O9/c1-27(2)36-39(48)45-33(24-30-18-12-9-13-19-30)42(51)55-37(28(3)4)40(49)47(8)35(26-32-22-16-11-17-23-32)44(53)56-38(29(5)6)41(50)46(7)34(43(52)54-36)25-31-20-14-10-15-21-31/h9-23,27-29,33-38H,24-26H2,1-8H3,(H,45,48)/t33-,34-,35-,36+,37+,38+/m0/s1
|
|
| InChIKey |
CPKHOIZGUQVKAF-YAQJXRFXSA-N
|
|
| Synonyms |
Beauvericin D; (3S,6R,9S,12R,15S,18R)-3,9,15-tribenzyl-6,12,18-triisopropyl-4,10-dimethyl-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone
|
|
| CAS | NA | |
| PubChem CID | 3007986 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 769.9 | ALogp: | 8.2 |
| HBD: | 1 | HBA: | 9 |
| Rotatable Bonds: | 9 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 149.0 | Aromatic Rings: | 4 |
| Heavy Atoms: | 56 | QED Weighted: | 0.233 |
| Caco-2 Permeability: | -5.145 | MDCK Permeability: | 0.00010931 |
| Pgp-inhibitor: | 1 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.017 |
| 30% Bioavailability (F30%): | 0.175 |
| Blood-Brain-Barrier Penetration (BBB): | 0.007 | Plasma Protein Binding (PPB): | 96.16% |
| Volume Distribution (VD): | 1.002 | Fu: | 0.89% |
| CYP1A2-inhibitor: | 0.008 | CYP1A2-substrate: | 0.033 |
| CYP2C19-inhibitor: | 0.409 | CYP2C19-substrate: | 0.865 |
| CYP2C9-inhibitor: | 0.535 | CYP2C9-substrate: | 0.108 |
| CYP2D6-inhibitor: | 0.018 | CYP2D6-substrate: | 0.134 |
| CYP3A4-inhibitor: | 0.782 | CYP3A4-substrate: | 0.914 |
| Clearance (CL): | 4.612 | Half-life (T1/2): | 0.059 |
| hERG Blockers: | 0.131 | Human Hepatotoxicity (H-HT): | 0.992 |
| Drug-inuced Liver Injury (DILI): | 0.988 | AMES Toxicity: | 0.012 |
| Rat Oral Acute Toxicity: | 0.874 | Maximum Recommended Daily Dose: | 0.573 |
| Skin Sensitization: | 0.023 | Carcinogencity: | 0.032 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
| Respiratory Toxicity: | 0.024 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002627 | ![]() |
0.867 | D0J7XL | ![]() |
0.333 | ||
| ENC004891 | ![]() |
0.435 | D02XIY | ![]() |
0.332 | ||
| ENC002483 | ![]() |
0.399 | D0U4YG | ![]() |
0.310 | ||
| ENC003692 | ![]() |
0.386 | D03DEI | ![]() |
0.308 | ||
| ENC003559 | ![]() |
0.385 | D05MNW | ![]() |
0.298 | ||
| ENC002857 | ![]() |
0.384 | D07XGH | ![]() |
0.298 | ||
| ENC002129 | ![]() |
0.383 | D07DSQ | ![]() |
0.288 | ||
| ENC000948 | ![]() |
0.381 | D0E2OU | ![]() |
0.287 | ||
| ENC002484 | ![]() |
0.381 | D0U5GB | ![]() |
0.279 | ||
| ENC002971 | ![]() |
0.376 | D06TFE | ![]() |
0.277 | ||